COLETTE SONG,HARPREET DR. SINGH,JENS FRITSCHE,OLIVER DR. SCHOOR,TONI DR. WEINSCHENK,ANDREA DR. MAHR
申请号：
ARP160100819
公开号：
AR104114A1
申请日:
2016.03.28
申请国别(地区):
AR
年份:
2017
代理人:
摘要：
Claim 1: A peptide characterized in that it comprises an amino acid sequence that is chosen from the group consisting of SEQ ID No. 1 to SEQ ID No. 114, and variant sequences thereof that are at least 88% homologous to SEQ ID No. 1 to SEQ ID No. 114； and a pharmaceutically acceptable salt thereof, wherein said peptide is not a full length polypeptide. Claim 7: A nucleic acid, characterized in that it encodes a peptide or variant thereof according to any one of claims 1 to 6, optionally connected to a heterologous promoter sequence. Claim 12: An in vitro method for producing activated T lymphocytes,In particular, the method comprises contacting T cells in vitro with viruses on the surface of appropriate antigen display cells of one or two kinds of people with antigens, or imitating artificial buildings of antigen display cells for a long time. Activation of these T cells in the form of a specific antigen, in which it is a peptide according to any of the requirements of items 1 to 6. Claim 15: antibodies, in particular those that are soluble or membrane bound,It is characterized in that it specifically recognizes peptides or their substitutes in accordance with any one of the requirements of 1-5, preferably in accordance with any one of the requirements of 1-5, when Binding MHC molecules, peptides or their substitutes are used, in which antibodies have additional bactericidal functions, such as Domain or immune stimulating toxin. Claim 18: use of alpha and beta HCH in accordance with claim 16, characterized by the selection of lung cancer, brain cancer, gastric cancer, rectal cancer, liver cancer, pancreatic cancer, prostate cancer, leukemia, breast cancer, melanoma,Ovarian, esophageal, and other tumors show overexposure leading to peptides from SEQ ID 1 to SEQ ID 114. Claim 40: a default characterized by the specific recognition of peptides or their variants based on any 1-5 claims, preferably in combination with any one of the 1-5 claims by an MHC molecule.Reivindic
